Compositions and methods for treating celiac sprue disease

JP2023548083A5Inactive Publication Date: 2024-11-06UNIV OF WASHINGTON +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023525049
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-10-30
Filing Date
2021-10-29
Publication Date
2024-11-06
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current treatments for celiac sprue and non-celiac gluten sensitivity (NCGS) are inadequate, as existing enzyme treatments trigger an immune response in the intestine and are ineffective in degrading gluten peptides under acidic gastrointestinal conditions.

Method used

Development of polypeptides with specific amino acid sequences, such as SEQ ID NO:1 and SEQ ID NO:8, capable of cleaving gliadin peptides effectively under acidic conditions, and their use in compositions for oral administration to treat celiac sprue and NCGS.

Benefits of technology

The polypeptides achieve significant degradation of gluten peptides, reducing intestinal inflammation and associated symptoms in celiac sprue and NCGS, providing a therapeutic option that does not trigger an immune response.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present disclosure relates to polypeptides capable of cleaving gluten proteins, such as gliadin, nucleic acid molecules encoding such polypeptides, pharmaceutical compositions comprising such polypeptides, and their uses for treating celiac sprue disease and / or non-celiac gluten sensitivity (NCGS).
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Related applications This application claims priority to U.S. Provisional Application No. 63 / 108,163, filed on 30 October 2020, which is incorporated herein by reference in its entirety.

[0002] Sequence listing reference This application includes a sequence listing filed electronically in ASCII format, which is incorporated herein by reference in its entirety. A copy of the above ASCII file, created on 15 October 2021, is named 7281_50WO2_Seqlisting_ST25.txt and has a size of 31,599 bytes.

[0003] Areas of disclosure This disclosure relates to compositions capable of cleaving gluten peptides, such as gliadin, and their use in the treatment of gluten sensitivity, including celiac prussis. [Background technology]

[0004] Celiac sprue is a very common disease in which a food protein known as "gluten," found in wheat, barley, and rye products, triggers an immune response in the small intestine of genetically predisposed individuals. The resulting inflammation can lead to the breakdown of the villi in the small intestine, interfering with nutrient absorption. Symptoms can appear in early or late childhood and range widely in severity, from diarrhea, fatigue, and weight loss to abdominal distension, anemia, and neurological symptoms. There is currently no effective treatment for this life-threatening disease other than completely eliminating gluten from the diet. Although celiac sprue is largely underdiagnosed, its prevalence in the United States and Europe is estimated to be 0.5–1.0% of the population. In addition to celiac sprouts, a significant portion of the population is thought to suffer from non-celiac gluten sensitivity (NCGS), a condition caused by gluten intake but with a different mechanism than celiac disease, although the symptoms are often indistinguishable from those of celiac sprouts. Due to the harsh physical and chemical requirements for specifically and efficiently breaking down gluten-derived peptides in the severe and highly acidic environment of the human digestive tract, it is difficult to identify suitable naturally occurring enzymes as oral treatments for celiac disease and NCGS. Since gluten peptides initiate an immune response immediately upon entering the intestines, it is essential that any oral enzyme therapy for celiac disease destroys these immunogenic gluten regions within the digestive compartment, thereby preventing these gluten peptides from causing intestinal damage due to inflammation. [Overview of the Initiative]

[0005] Certain aspects of this disclosure relate to polypeptides comprising an amino acid sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% sequence identity with respect to the amino acid sequence shown in SEQ ID NO: 1. In some aspects, the polypeptide comprises an amino acid sequence having at least 85% sequence identity with respect to the amino acid sequence shown in SEQ ID NO: 1. In some aspects, the polypeptide comprises an amino acid sequence having at least 90% sequence identity with respect to the amino acid sequence shown in SEQ ID NO: 1. In some aspects, the polypeptide comprises an amino acid sequence having at least 95% sequence identity with respect to the amino acid sequence shown in SEQ ID NO: 1. In some aspects, the polypeptide comprises an amino acid sequence having at least 99% sequence identity with respect to the amino acid sequence shown in SEQ ID NO: 1. In some aspects, the polypeptide comprises an amino acid sequence having at least 99% sequence identity with respect to the amino acid sequence shown in SEQ ID NO: 1.

[0006] In some embodiments, the amino acid residue corresponding to amino acid 467 in SEQ ID NO: 6 is Ser. In some embodiments, the amino acid residue corresponding to amino acid 267 in SEQ ID NO: 6 is Glu. In some embodiments, the amino acid residue corresponding to amino acid 271 in SEQ ID NO: 6 is Asp.

[0007] In some embodiments, polypeptides are capable of cleaving gliadin.

[0008] Certain aspects of this disclosure relate to polypeptides comprising an amino acid sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% sequence identity with respect to the amino acid sequence shown in SEQ ID NO: 8. In some aspects, the polypeptide comprises an amino acid sequence having at least 85% sequence identity with respect to the amino acid sequence shown in SEQ ID NO: 8. In some aspects, the polypeptide comprises an amino acid sequence having at least 90% sequence identity with respect to the amino acid sequence shown in SEQ ID NO: 8. In some aspects, the polypeptide comprises an amino acid sequence having at least 95% sequence identity with respect to the amino acid sequence shown in SEQ ID NO: 8. In some aspects, the polypeptide comprises an amino acid sequence having at least 99% sequence identity with respect to the amino acid sequence shown in SEQ ID NO: 8. In some aspects, the polypeptide comprises an amino acid sequence having at least 99% sequence identity with respect to the amino acid sequence shown in SEQ ID NO: 8.

[0009] In some embodiments, the amino acid residue corresponding to amino acid 278 in SEQ ID NO: 3 is Ser. In some embodiments, the amino acid residue corresponding to amino acid 78 in SEQ ID NO: 3 is Glu. In some embodiments, the amino acid residue corresponding to amino acid 82 in SEQ ID NO: 3 is Asp.

[0010] In some embodiments, polypeptides are capable of cleaving gliadin.

[0011] Certain embodiments of this disclosure relate to a polypeptide comprising an amino acid sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% sequence identity with respect to the amino acid sequence shown in SEQ ID NO: 1, wherein the polypeptide comprises the amino acid sequence shown in SEQ ID NO: 8. In some embodiments, the polypeptide comprises an amino acid sequence having at least 85% sequence identity with respect to the amino acid sequence shown in SEQ ID NO: 1. In some embodiments, the polypeptide comprises an amino acid sequence having at least 90% sequence identity with respect to the amino acid sequence shown in SEQ ID NO: 1. In some embodiments, the polypeptide comprises an amino acid sequence having at least 95% sequence identity with respect to the amino acid sequence shown in SEQ ID NO: 1. In some embodiments, the polypeptide comprises an amino acid sequence having at least 99% sequence identity with respect to the amino acid sequence shown in SEQ ID NO: 1. In some embodiments, the polypeptide comprises the amino acid sequence shown in SEQ ID NO: 1.

[0012] In some embodiments, the amino acid residue corresponding to amino acid 467 in SEQ ID NO: 6 is Ser. In some embodiments, the amino acid residue corresponding to amino acid 267 in SEQ ID NO: 6 is Glu. In some embodiments, the amino acid residue corresponding to amino acid 271 in SEQ ID NO: 6 is Asp.

[0013] In some embodiments, polypeptides are capable of cleaving gliadin.

[0014] In some embodiments, the polypeptide includes a histidine tag, which is fused at the C-terminus of the polypeptide. In some embodiments, the histidine tag includes the amino acid sequence (GSTENLYFQSGALEHHHHHH) shown in SEQ ID NO: 17. In some embodiments, the histidine tag includes the amino acid sequence (X) shown in SEQ ID NO: 15. N PQ(L / Q)PX N HHHHHH) [where X NThis is a linker consisting of 1 to 25 amino acid residues. It includes a cleavable histidine tag, but is not limited to one containing ]. In some embodiments, the cleavable histidine tag includes the amino acid sequence (GSSGSSGSQPQLPYGSSGSSGSHHHHHH) shown in SEQ ID NO: 16.

[0015] Certain aspects of this disclosure relate to nucleic acid molecules encoding polypeptides disclosed herein.

[0016] Certain aspects of this disclosure relate to nucleic acid expression vectors comprising nucleic acid molecules disclosed herein.

[0017] Certain aspects of this disclosure relate to recombinant host cells comprising nucleic acid molecules or nucleic acid expression vectors disclosed herein.

[0018] Certain aspects of this disclosure relate to pharmaceutical compositions comprising a polypeptide disclosed herein, a nucleic acid molecule disclosed herein, a nucleic acid expression vector disclosed herein, a recombinant host cell disclosed herein, or any combination thereof, and a pharmaceutically acceptable carrier.

[0019] Certain embodiments of this disclosure are methods for treating celiac prue or non-celiac gluten sensitivity (NCGS), comprising administering to an individual suffering from celiac prue or NCGS an amount effective to treat celiac prue or NCGS of a polypeptide, a nucleic acid molecule, a nucleic acid expression vector, a recombinant host cell, or a pharmaceutical composition disclosed herein. In some embodiments, the polypeptide, nucleic acid molecule, nucleic acid expression vector, recombinant host cell, or pharmaceutical composition is administered orally.

[0020] In some embodiments, the present disclosure relates to a polypeptide comprising an amino acid sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 1, wherein the first amino acid at the N-terminus of the polypeptide is Ser (S). In some embodiments, the polypeptide has gliadinase activity.

[0021] In some embodiments, the present disclosure relates to a polypeptide comprising an amino acid sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 99%, or about 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 1, wherein the polypeptide does not contain Met (M) at the N-terminus of the polypeptide.

[0022] In some embodiments, the present disclosure relates to a polypeptide comprising an amino acid sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 23, wherein Xaa within SEQ ID NO: 23 is not Met (M).

[0023] In some embodiments, the present disclosure relates to a polypeptide comprising an amino acid sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 1, wherein the first amino acid at the N-terminus of the polypeptide is Ser (S), and the polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 8.

[0024] In some embodiments, the first two N-terminal amino acids of the polypeptide, from the N-terminus to the C-terminus, are Ser-Asp (SD). In some embodiments, the first three N-terminal amino acids of the polypeptide, from the N-terminus to the C-terminus, are Ser-Asp-Met (SDM). In some embodiments, the first four N-terminal amino acids of the polypeptide, from the N-terminus to the C-terminus, are Ser-Asp-Met-Glu (SDME).

[0025] In some embodiments, the polypeptides disclosed herein include an amino acid sequence having at least 85% sequence identity to the amino acid sequence set forth in SEQ ID NO: 1. In some embodiments, the polypeptides disclosed herein include an amino acid sequence having at least 90% sequence identity to the amino acid sequence set forth in SEQ ID NO: 1. In some embodiments, the polypeptides disclosed herein include an amino acid sequence having at least 95% sequence identity to the amino acid sequence set forth in SEQ ID NO: 1. In some embodiments, the polypeptides disclosed herein include an amino acid sequence having at least 99% sequence identity to the amino acid sequence set forth in SEQ ID NO: 1. In some embodiments, the polypeptides disclosed herein include the amino acid sequence set forth in SEQ ID NO: 1.

[0026] In some embodiments of the polypeptides disclosed herein, the amino acid residue corresponding to amino acid 467 of SEQ ID NO: 1 is Ser. In some embodiments of the polypeptides disclosed herein, the amino acid residue corresponding to amino acid 267 of SEQ ID NO: 1 is Glu. In some embodiments of the polypeptides disclosed herein, the amino acid residue corresponding to amino acid 271 of SEQ ID NO: 1 is Asp.

[0027] In some embodiments of the present disclosure, the polypeptide is capable of cleaving gliadin. In some embodiments, the polypeptide has improved enzymatic activity compared to Kuma011.

[0028] In some embodiments, the polypeptide disclosed herein further comprises a histidine tag fused to the polypeptide at its C-terminus. In some embodiments, the histidine tag comprises the amino acid sequence (GSTENLYFQSGALEHHHHHH) shown in SEQ ID NO: 17. In some embodiments, the histidine tag comprises a cleavable histidine tag comprising the amino acid sequence (XNPQ(L / Q)PXNHHHHHH) [wherein XN is a linker of 1 to 25 amino acid residues] shown in SEQ ID NO: 15, but not limited to this. In some embodiments, the cleavable histidine tag comprises the amino acid sequence (GSSGSSGSQPQLPYGSSGSSGSHHHHHH) shown in SEQ ID NO: 16.

[0029] In some aspects, this disclosure relates to nucleic acid molecules encoding the polypeptides described herein. In some aspects, this disclosure relates to nucleic acid expression vectors comprising the nucleic acid molecules described herein.

[0030] In some embodiments, this disclosure relates to recombinant host cells comprising nucleic acid molecules or nucleic acid expression vectors described herein. In some embodiments, the host cells are prokaryotic. In some embodiments, the host cells are eukaryotic.

[0031] In some embodiments, this disclosure relates to pharmaceutical compositions comprising a polypeptide, nucleic acid molecule, nucleic acid expression vector, or recombinant host cell, or any combination thereof, as described herein, and a pharmaceutically acceptable carrier.

[0032] In some aspects, the Disclosure relates to a method for treating celiac sprue or non-celiac gluten sensitivity (NCGS) in a subject, the method comprising administering to the subject suffering from celiac sprue or NCGS an amount effective to treat the celiac sprue or NCGS of a polypeptide, nucleic acid molecule, nucleic acid expression vector, recombinant host cell, or pharmaceutical composition described herein.

[0033] In some embodiments, the Disclosure relates to a method for reducing inflammation associated with celiac sprue or non-celiac gluten sensitivity (NCGS) in a subject, comprising reducing the inflammation by administering to the subject suffering from celiac sprue or NCGS an amount effective in reducing the inflammation associated with celiac sprue or NCGS of the polypeptide, nucleic acid molecule, nucleic acid expression vector, recombinant host cell, or pharmaceutical composition described herein. In some embodiments, the polypeptide, nucleic acid molecule, nucleic acid expression vector, recombinant host cell, or pharmaceutical composition is administered orally.

[0034] In some embodiments, the present disclosure relates to a method for breaking down gluten in a food, the method comprising breaking down the gluten in the food by contacting the food with a polypeptide or pharmaceutical composition described herein in an amount effective for breaking down the gluten.

[0035] In some embodiments, the present disclosure relates to a method for degrading gliadin in a food, comprising degrading the gliadin in the food by contacting the food with a polypeptide or pharmaceutical composition described herein in an amount effective for degrading the gliadin.

[0036] In some embodiments, the method breaks down at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 99%, or about 100% of the gluten or gliadin in the food. In some embodiments, the method breaks down the gluten or gliadin in the food in less than about 1.5 hours, less than about 1 hour, less than about 45 minutes, less than about 40 minutes, less than about 30 minutes, less than about 25 minutes, less than about 20 minutes, less than about 15 minutes, less than about 10 minutes, or less than about 5 minutes. In some embodiments, the method breaks down the gluten or gliadin in the food under pH values ​​of less than about 6.5, less than about 6.0, less than about 5.5, less than about 5.0, less than about 4.5, less than about 4.0, less than about 3.5, less than about 3.0, less than about 2.5, less than 2.0, or less than about 1.5. [Modes for carrying out the invention]

[0037] This disclosure provides gliadinases capable of degrading gliadin peptides. Some aspects of this disclosure relate to polypeptides comprising an amino acid sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% sequence identity with respect to the amino acid sequence shown in SEQ ID NO: 1, wherein the first amino acid at the N-terminus of the polypeptide is Ser(S). In some aspects, the polypeptide does not contain Met(M) at the N-terminus of the polypeptide. In some aspects, the polypeptide comprises the amino acid sequence shown in SEQ ID NO: 8.

[0038] 1.Definition To make this disclosure easier to understand, certain terms are defined first. Unless otherwise defined herein, scientific and technical terms used in connection with this disclosure have the meanings generally understood by those skilled in the art. The meaning and scope of terms will be clear, but in the event of any potential ambiguity, the definitions provided herein shall prevail over any dictionary or external definitions.

[0039] Furthermore, whenever parameter values ​​or ranges of values ​​are enumerated, it should be noted that intermediate values ​​and ranges between the enumerated values ​​are also intended to be part of this disclosure.

[0040] Where used herein, unless otherwise clearly indicated by the context, the singular forms “a,” “an,” and “the” include multiple references. Where used herein, “and” is synonymous with “or” unless otherwise explicitly indicated. Where used herein, the terms “equip,” “possess,” “include,” and “contain” are to be interpreted as open-ended terms (i.e., “include but not limited to”). Where used herein, the enumeration of value ranges is intended simply as a shorthand method to refer individually to each distinct value enumerated or falling within the range, unless otherwise indicated herein, and each distinct value is incorporated herein as if it were enumerated individually.

[0041] The terms "about" or "approximately" mean within 10%, 5%, or more preferably 1% of a given value or range.

[0042] The term "amino acid" refers to 20 common, naturally occurring amino acids. These naturally occurring amino acids include alanine (Ala; A), asparagine (Asn; N), aspartic acid (Asp; D), arginine (Arg; R), cysteine ​​(Cys; C), glutamic acid (Glu; E), glutamine (Gln; Q), glycine (Gly; G), histidine (His; H), isoleucine (Ile; I), leucine (Leu; L), lysine (Lys; K), methionine (Met; M), phenylalanine (Phe; F), proline (Pro; P), serine (Ser; S), threonine (Thr; T), tryptophan (Trp; W), tyrosine (Tyr; Y), and valine (Val; V).

[0043] The terms "celiac disease" and "celiac-sprue disease" are used interchangeably and refer to a medical condition characterized by an inflammatory response to immunogenic peptides and related proteins within gluten, the main protein in wheat flour. Upon ingestion, α-gliadin is partially broken down by gastrointestinal proteases into an oligopeptide referred to herein as "gliadin." Due to its abnormally high proline and glutamine content, gliadin is resistant to further protein degradation in the stomach.

[0044] As used herein, a “conservative amino acid substitution” is a substitution in which one amino acid residue is replaced by another amino acid residue having a side chain (R group) with similar chemical properties (e.g., charge or hydrophobicity). Generally, conservative amino acid substitutions do not substantially alter the functional properties of a protein. If two or more amino acid sequences differ from each other due to a conservative substitution, the sequence identity percentage or degree of similarity may be adjusted up to compensate for the conservative nature of the substitution. Means for making this adjustment are well known to those skilled in the art. See, for example, Pearson (1994) Methods Mol. Biol. 24:307-331, which is incorporated herein by reference. Examples of amino acids with side chains having similar chemical properties include: (1) aliphatic side chains: glycine, alanine, valine, leucine, and isoleucine; (2) aliphatic-hydroxyl side chains: serine and threonine; (3) amide-containing side chains: asparagine and glutamine; (4) aromatic side chains: phenylalanine, tyrosine, and tryptophan; (5) basic side chains: lysine, arginine, and histidine; (6) acidic side chains: aspartic acid and glutamic acid; and (7) sulfur-containing side chains: cysteine ​​and methionine. Preferred conserved amino acid substitutions include valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, glutamic acid-aspartic acid, and asparagine-glutamine. Alternatively, a conservative substitution is any change with a positive value in the PAM250 log-possibility matrix, as disclosed in Gonnet et al. (1992) Science 256:1443-1445, which is incorporated herein by reference. A “moderately conservative” substitution is any change with a non-negative value in the PAM250 log-possibility matrix.

[0045] As used herein, the terms “degradate” and “degradation” mean to break down or degrade a target, such as polypeptides, such as gluten, gliadin, and associated proteins, into smaller oligopeptides. In certain embodiments, the degradation of gliadin results in a reduction and / or removal of immunogenic peptides associated with celiac disease.

[0046] As used herein, the term “gliazinase” refers to a polypeptide (enzyme) that can effectively break down one or more gliadins. As used herein, the term “gliadin” refers to the proline (P) and glutamine (Q)-rich peptide components of gluten. Exemplary gliadins include PQLP (SEQ ID NO: 9) or PQQP (SEQ ID NO: 10) motifs (such as PFPQPQLPY (SEQ ID NO: 11) and / or PFPQPQQPF (SEQ ID NO: 12)). In certain embodiments, gliadinase breaks down one or more gliadins under acidic conditions, for example, at pH 4 or below.

[0047] As used herein, the term “mutation” means the insertion, deletion, or substitution of one or more amino acids in a polypeptide or one or more nucleotides in a polynucleotide.

[0048] As used herein, the term “variant” refers to a polypeptide or polynucleotide comprising one or more amino acid or nucleotide insertions, substitutions, or deletions compared to a reference polypeptide or polynucleotide. In certain embodiments, a variant polypeptide or polynucleotide has at least about 75% amino acid or nucleotide sequence identity with respect to a reference polypeptide or polynucleotide sequence, e.g., at least about 80%, at least about 85%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% sequence identity. In some embodiments, a variant of a reference polypeptide or polynucleotide maintains one or more functions, activities, and / or structures of the reference polypeptide or polynucleotide. For example, a variant of gliadinase disclosed herein maintains the function of effectively grading gluten and / or gliadin. In another example, a polynucleotide variant encoding gliadinase encodes functional gliadinase.

[0049] Typically, sequence identity is measured using sequence analysis software. Protein analysis software matches similar sequences using similarity measures assigned to various substitutions, deletions, and other modifications, including conserved amino acid substitutions. For example, GCG software includes programs such as "Gap" and "Bestfit," which can be used with default parameters to determine sequence homology or sequence identity between closely related polypeptides, such as homologous polypeptides from different species, or between wild-type proteins and their mutaines. See, for example, GCG Version 6.1. Polypeptide sequences can also be compared using FASTA, a program within GCG Version 6.1, using default or recommended parameters. FASTA (e.g., FASTA2 and FASTA3) provides alignment and sequence identity (%) of the region with the most overlap between the query sequence and the search sequence (Pearson (2000) above). Another non-limiting example of an algorithm that can be used to compare the sequences of this disclosure with a database containing numerous sequences from different organisms is the computer program BLAST, e.g., BLASTP or TBLASTN using default parameters. For example, see Altschul et al. (1990) J.Mol.Biol.215:403-410 and Altschul et al. (1997) Nucleic Acids Res.25:3389-402, which are incorporated in their entirety by reference herein.

[0050] As used herein, “treatment” or “treating” means an action that produces a beneficial effect, e.g., improvement of at least one symptom of a disease or disorder. A beneficial effect can take the form of improvement compared to baseline, i.e., improvement from a measurement or observation prior to the initiation of treatment according to the method. A beneficial effect can also take the form of cessation, slowing, delaying, or stabilization of damage, e.g., inflammation, that can result in the breakdown of the villi of the small intestine (including hyperplasia and villous atrophy), characterized by celiac sprout or non-celiac gluten sensitivity (NCGS). Effective treatment may refer to the alleviation or prevention of at least one symptom of celiac sprout or NCGS. Such effective treatments may reduce and inhibit the worsening of intestinal and / or extraintestinal clinical symptoms of celiac sprout or NCGS, such as diarrhea, abdominal pain, malnutrition, anemia, osteoporosis, or any known symptoms; limit or prevent recurrence of celiac sprout in patients with a history of the disorder; limit or prevent recurrence of symptoms in patients with a history of celiac sprout or NCGS; and / or limit the development of celiac sprout or NCGS in subjects at risk of developing celiac sprout or NCGS, or who have not yet shown clinical efficacy from celiac sprout or NCGS.

[0051] In some aspects, the treatment reduces inflammation in the small intestine. An effective reduction in inflammation may include a reduction of at least about 1%, at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 99%, or about 100% compared to the inflammation before treatment. The reduction in inflammation can be measured by any means.

[0052] Any individual experiencing gluten sensitivity can be treated according to the methods of this disclosure. In some embodiments, the individual has celiac sprue. In some embodiments, the individual has NCGS. In some embodiments, the individual is a human subject. In some embodiments, the individual experiences one or more symptoms associated with gluten sensitivity. In some embodiments, the individual is asymptomatic.

[0053] As used herein, “effective amount” means an amount of polypeptide sufficient to induce a reduction in the severity or frequency of one or more symptoms of gluten sensitivity, such as celiac sprout or NCGS.

[0054] The polypeptides disclosed herein can be formulated as pharmaceutical compositions such as those disclosed above, and can be administered by any preferred route, including orally, parenterally, inhaled spray, or topically, in a dosage unit formulation containing a conventional pharmaceutically acceptable carrier, adjuvant, and vehicle.

[0055] All aspects of this disclosure may be used in combination unless otherwise explicitly indicated by the context. All references cited are incorporated by reference in their entirety. Unless otherwise noted, the techniques used in this application are referenced in Molecular Cloning: A Laboratory Manual (Sambrook, et al., 1989, Cold Spring Harbor Laboratory Press), Gene Expression Technology (Methods in Enzymology, Vol. 185, edited by D. Goeddel, 1991, Academic Press, San Diego, CA), Guide to Protein Purification in Methods in Enzymology (MPDeutscher, ed., (1990) Academic Press, Inc.), PCR Protocols: A Guide to Methods and Applications (Innis, et al., 1990, Academic Press, San Diego, CA), Culture of Animal Cells: A Manual of Basic Technique, 2 nd This can be found in several well-known references, such as Ed. (RIFreshney, 1987, Liss, Inc., New York, NY), Gene Transfer and Expression Protocols, pp. 109-128, ed. EJ Murray, The Humana Press Inc., Clifton, NJ), and Ambion 1998 Catalog (Ambion, Austin, TX).

[0056] 2. Compositions of the Disclosure This disclosure provides gliadinases that effectively degrade gliadin. This disclosure is at least in part based on the discovery that various polypeptides described herein, containing one or more mutations compared to Kuma011, have improved properties, including increased gliadin-degrading activity, compared to Kuma011 and other known gliadinases such as SC-PEP (Sphingomonas encapsulated peptidase) and endoprotease EPB2. In certain embodiments, the various polypeptides described herein have improved gliadinase activity than Kuma011 and other known gliadinases under acidic conditions.

[0057] In some embodiments, the Disclosure provides a polypeptide having an amino acid sequence that is at least 75% identical to the amino acid sequence shown in SEQ ID NO: 6, wherein (a) residue 467 is Ser, residue 267 is Glu, and residue 271 is Asp, and (b) the polypeptide has an amino acid substitution compared to SEQ ID NO: 6 in one or more residues selected from the group consisting of 221, 262E, 268, 269, 270, 319A, 320, 354E / Q / R / Y, 358S / Q / T, 368F / Q, 399, 402, 406, 424, 449, 461, 463, 105, 171, 172, 173, 174, and 456. In some embodiments, the polypeptide includes amino acid substitutions compared to SEQ ID NO: 6 in one or more residues selected from the group consisting of 221, 262E, 268, 269, 270, 319A, 320, 354E / Q / R / Y, 358S / Q / T, 368F / Q, 399, 402, 406, 424, 449, 461, and 463. [Table 1-1] [Table 1-2]

[0058] As used herein, Kuma010 includes Kuma011, which is formed by linking the C-terminus of the Kuma010 sequence to the histidine tag sequence GSTENLYFQSGALEHHHHHH (SEQ ID NO: 17) via an amino bond.

[0059] In the sequences shown in Table 1, bolded residues represent the N-terminal portion present in the untreated polypeptide (i.e., cleaved during processing), while non-bold fonts represent residues present in the treated polypeptide (i.e., mature peptide sequences). The numbers in parentheses represent residue numbers; when two numbers are separated by a " / ", the left number is the residue number in the untreated version, and the right number is the residue number in the treated version. Sequence ID 6 is the untreated Kuma011, and Sequence ID 3 is the treated Kuma011. Therefore, a polypeptide containing the amino acid sequence shown in Sequence ID 6 (full-length Kuma011 polypeptide) also necessarily contains the amino acid sequence shown in Sequence ID 3 (mature Kuma011 polypeptide). Sequence ID 1 is the untreated Kuma062-M, and Sequence ID 8 is the treated Kuma062-M. Therefore, a polypeptide containing the amino acid sequence shown in SEQ ID NO: 1 (full-length Kuma062-M polypeptide) inevitably also contains the amino acid sequence shown in SEQ ID NO: 8 (mature Kuma062-M polypeptide).

[0060] In some embodiments, the gliadinase of the Disclosure has serine (Ser or S) at its N-terminus. In some embodiments, the gliadinase of the Disclosure has an SD motif at its N-terminus. In some embodiments, the gliadinase of the Disclosure has an SDM motif at its N-terminus. In some embodiments, the gliadinase of the Disclosure has SDME (SEQ ID NO: 21) at its N-terminus. In such embodiments, the first amino acid (polypeptide at position 1 from its N-terminus) is S, the second amino acid (polypeptide at position 2 from its N-terminus) is D, the third amino acid (polypeptide at position 3 from its N-terminus) is M, and the fourth amino acid (polypeptide at position 4 from its N-terminus) is E. In some embodiments, the oligopeptide is bound to the N-terminal S at its N-terminus, and the amino acid adjacent to S at its N-terminus is not methionine (M).

[0061] In some embodiments, the polypeptide (e.g., gliadinase) contains an amino acid sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% sequence identity with respect to the amino acid sequence shown in SEQ ID NO: 1. In some embodiments, the polypeptide contains an amino acid sequence having at least 75% sequence identity with respect to the amino acid sequence shown in SEQ ID NO: 1. In some embodiments, the polypeptide contains an amino acid sequence having at least 80% sequence identity with respect to the amino acid sequence shown in SEQ ID NO: 1. In some embodiments, the polypeptide contains an amino acid sequence having at least 85% sequence identity with respect to the amino acid sequence shown in SEQ ID NO: 1. In some embodiments, the polypeptide contains an amino acid sequence having at least 90% sequence identity with respect to the amino acid sequence shown in SEQ ID NO: 1. In some embodiments, the polypeptide contains an amino acid sequence having at least 95% sequence identity with the amino acid sequence shown in SEQ ID NO: 1. In some embodiments, the polypeptide contains an amino acid sequence having at least 96% sequence identity with the amino acid sequence shown in SEQ ID NO: 1. In some embodiments, the polypeptide contains an amino acid sequence having at least 97% sequence identity with the amino acid sequence shown in SEQ ID NO: 1. In some embodiments, the polypeptide contains an amino acid sequence having at least 98% sequence identity with the amino acid sequence shown in SEQ ID NO: 1. In some embodiments, the polypeptide contains an amino acid sequence having at least 99% sequence identity with the amino acid sequence shown in SEQ ID NO: 1. In some embodiments, the polypeptide contains Ser at the amino acid residue corresponding to amino acid 467 of SEQ ID NO: 1. In some embodiments, the polypeptide contains Glu at the amino acid residue corresponding to amino acid 267 of SEQ ID NO: 1. In some embodiments, the polypeptide contains Asp at the amino acid residue corresponding to amino acid 271 of SEQ ID NO: 1.

[0062] In some embodiments, the polypeptide (e.g., gliadinase) contains an amino acid sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% sequence identity with respect to the amino acid sequence shown in SEQ ID NO: 8. In some embodiments, the polypeptide contains the amino acid sequence shown in SEQ ID NO: 8. In some embodiments, the polypeptide contains an amino acid sequence having at least 75% sequence identity with respect to the amino acid sequence shown in SEQ ID NO: 8. In some embodiments, the polypeptide contains an amino acid sequence having at least 80% sequence identity with respect to the amino acid sequence shown in SEQ ID NO: 8. In some embodiments, the polypeptide contains an amino acid sequence having at least 85% sequence identity with respect to the amino acid sequence shown in SEQ ID NO: 8. In some embodiments, the polypeptide contains an amino acid sequence having at least 90% sequence identity with respect to the amino acid sequence shown in SEQ ID NO: 8. In some embodiments, the polypeptide contains an amino acid sequence having at least 95% sequence identity with the amino acid sequence shown in SEQ ID NO: 8. In some embodiments, the polypeptide contains an amino acid sequence having at least 96% sequence identity with the amino acid sequence shown in SEQ ID NO: 8. In some embodiments, the polypeptide contains an amino acid sequence having at least 97% sequence identity with the amino acid sequence shown in SEQ ID NO: 8. In some embodiments, the polypeptide contains an amino acid sequence having at least 98% sequence identity with the amino acid sequence shown in SEQ ID NO: 8. In some embodiments, the polypeptide contains an amino acid sequence having at least 99% sequence identity with the amino acid sequence shown in SEQ ID NO: 8. In some embodiments, the polypeptide contains Ser at the amino acid residue corresponding to amino acid 278 in SEQ ID NO: 3. In some embodiments, the polypeptide contains Glu at the amino acid residue corresponding to amino acid 78 in SEQ ID NO: 3. In some embodiments, the polypeptide contains Asp at the amino acid residue corresponding to amino acid 82 in SEQ ID NO: 3.

[0063] In some embodiments, the polypeptide (e.g., gliadinase) comprises an amino acid sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% sequence identity with respect to the amino acid sequence shown in SEQ ID NO: 1, and the polypeptide comprises the amino acid sequence shown in SEQ ID NO: 8. In some embodiments, the polypeptide comprises an amino acid sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% sequence identity with respect to the amino acid sequence shown in SEQ ID NO: 1, and the polypeptide comprises the amino acid sequence shown in SEQ ID NO: 8, and the polypeptide comprises Ser at the amino acid residue corresponding to amino acid 278 of SEQ ID NO: 3, Glu at the amino acid residue corresponding to amino acid 78 of SEQ ID NO: 3, and Asp at the amino acid residue corresponding to amino acid 82 of SEQ ID NO: 3.

[0064] In some embodiments, the polypeptide includes one or more amino acid deletions at the N-terminus or C-terminus compared to the amino acid sequence shown in SEQ ID NO: 1 or 6. In some embodiments, the polypeptide includes at least one amino acid deletion at the N-terminus compared to the amino acid sequence shown in SEQ ID NO: 1 or 6. In some embodiments, the polypeptide includes at least two amino acid deletions at the N-terminus compared to the amino acid sequence shown in SEQ ID NO: 1 or 6. In some embodiments, the polypeptide includes at least three amino acid deletions at the N-terminus compared to the amino acid sequence shown in SEQ ID NO: 1 or 6. In some embodiments, the polypeptide includes at least four amino acid deletions at the N-terminus compared to the amino acid sequence shown in SEQ ID NO: 1 or 6. In some embodiments, the polypeptide includes at least five amino acid deletions at the N-terminus compared to the amino acid sequence shown in SEQ ID NO: 1 or 6. In some embodiments, the polypeptide includes at least one amino acid deletion at the C-terminus compared to the amino acid sequence shown in SEQ ID NO: 1 or 6. In some embodiments, the polypeptide includes at least two amino acid deletions at the C-terminus compared to the amino acid sequence shown in SEQ ID NO: 1 or 6. In some embodiments, the polypeptide includes at least three amino acid deletions at the C-terminus compared to the amino acid sequence shown in SEQ ID NO: 1 or 6. In some embodiments, the polypeptide includes at least four amino acid deletions at the C-terminus compared to the amino acid sequence shown in SEQ ID NO: 1 or 6. In some embodiments, the polypeptide includes at least five amino acid deletions at the C-terminus compared to the amino acid sequence shown in SEQ ID NO: 1 or 6.

[0065] In some embodiments, the polypeptide includes one or more amino acid deletions at the N-terminus or C-terminus compared to the amino acid sequence shown in SEQ ID NO: 3 or 8. In some embodiments, the polypeptide includes at least one amino acid deletion at the N-terminus compared to the amino acid sequence shown in SEQ ID NO: 3 or 8. In some embodiments, the polypeptide includes at least two amino acid deletions at the N-terminus compared to the amino acid sequence shown in SEQ ID NO: 3 or 8. In some embodiments, the polypeptide includes at least three amino acid deletions at the N-terminus compared to the amino acid sequence shown in SEQ ID NO: 3 or 8. In some embodiments, the polypeptide includes at least four amino acid deletions at the N-terminus compared to the amino acid sequence shown in SEQ ID NO: 3 or 8. In some embodiments, the polypeptide includes at least five amino acid deletions at the N-terminus compared to the amino acid sequence shown in SEQ ID NO: 3 or 8. In some embodiments, the polypeptide includes at least one amino acid deletion at the C-terminus compared to the amino acid sequence shown in SEQ ID NO: 3 or 8. In some embodiments, the polypeptide includes at least two amino acid deletions at the C-terminus compared to the amino acid sequence shown in SEQ ID NO: 3 or 8. In some embodiments, the polypeptide includes at least three amino acid deletions at the C-terminus compared to the amino acid sequence shown in SEQ ID NO: 3 or 8. In some embodiments, the polypeptide includes at least four amino acid deletions at the C-terminus compared to the amino acid sequence shown in SEQ ID NO: 3 or 8. In some embodiments, the polypeptide includes at least five amino acid deletions at the C-terminus compared to the amino acid sequence shown in SEQ ID NO: 3 or 8.

[0066] As disclosed in the following examples, polypeptides according to some aspects of this disclosure are improved polypeptides, for example, for use in the treatment of celiac sprue. The polypeptide is a variant of either a processed (i.e., mature) polypeptide or a preprocessed (i.e., full-length) polypeptide corresponding to Sequence ID No. 4 (KUMAMAX®, hereinafter referred to as Kuma010; see WO2013 / 023151, which is incorporated herein in whole by reference). The polypeptide for treating celiac sprue is capable of cleaving the proline (P) and glutamine (Q)-rich components of gluten known as "gliadin," which are thought to be responsible for the majority of the immune response in most celiac sprue patients. The polypeptides of this disclosure exhibit superior activity at pH 4 in the degradation of peptides having a PQLP (SEQ ID NO: 9) or PQQP (SEQ ID NO: 10) motif (such as PFPQPQLPY (SEQ ID NO: 11) and / or PFPQPQQPF (SEQ ID NO: 12), which are representative substrates of gliadin), and / or demonstrate improved polypeptide production, compared with Kuma011 and other polypeptides disclosed as useful for the treatment of celiac sprue (see, for example, WO2015 / 023728 and WO2016 / 200880, respectively, incorporated herein by reference). Therefore, the polypeptides of this disclosure constitute a significantly improved therapeutic agent for the treatment of celiac sprue.

[0067] In some embodiments, the polypeptides disclosed herein are capable of grading peptides comprising amino acid sequences selected from PFPQPQLPY (SEQ ID NO: 11), PFPQPQQPF (SEQ ID NO: 12), LQLQPFPQPQLPYPQPQLPYPQPQLPYPQPQPF (SEQ ID NO: 13), and / or FLQPQQPFPQQPQQPYPQQPQQPFPQ (SEQ ID NO: 14) at pH 4.

[0068] The polypeptide of the first aspect of this disclosure comprises a pre-processed version of the polypeptide enzyme of this disclosure.

[0069] The polypeptide of the first aspect of this disclosure comprises a processed version of the polypeptide enzyme of this disclosure, which also degrades the PFPQPQLPY (SEQ ID NO: 11) peptide and / or the PFPQPQQPF (SEQ ID NO: 12) peptide at pH 4, as well as the LQLQPFPQPQLPYPQPQLPYPQPQLPYPQPQPF (SEQ ID NO: 13) and / or FLQPQQPFPQQPQQPYPQQPQQPFPQ (SEQ ID NO: 14).

[0070] As used herein, “at least 75% identical” or “having at least 75% sequence identity” means that the difference (including any amino acid substitutions, deletions, additions, or insertions) of the polypeptide’s full-length amino acid sequence (including any amino acid substitutions, deletions, additions, or insertions) from a reference sequence, for example, an amino acid sequence selected from SEQ ID NOs: 1 to 8, is 25% or less. In some embodiments, the polypeptide comprises or comprises an amino acid sequence that is at least 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence according to SEQ ID NO: 1 (pre-treated) or SEQ ID NO: 8 (treated).

[0071] Each polypeptide of any aspect of the polypeptides of this disclosure may contain the amino acid substitutions of SEQ ID NO: 1 or SEQ ID NO: 8 in 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 of the listed residues (depending on the aspect).

[0072] In one embodiment of a polypeptide according to the first aspect of this disclosure, the polypeptide contains one or more amino acid substitutions of SEQ ID NO: 6 in one or more residues selected from the group consisting of 221D / N / Q / H, 262E, 268S / T / A, 269L / T, 270A / T / V, 319A, 354E / Q / R / Y, 358S / Q / T, 368F / Q, 399Q, 402S / Q, 406S, 424K, 449E / N / Q, 461R, and 463A / L / M / Q / R / T / V. When used throughout, the number indicates the residue number in the SEQ ID NO: 6 or SEQ ID NO: 3 polypeptide sequence, and the single-letter amino acid abbreviation to the right of the number indicates the possible amino acid substitutions compared to the amino acid residue present at that position in SEQ ID NO: 6 or 3.

[0073] In another embodiment of the polypeptide of the first embodiment of this disclosure, the polypeptide includes the amino acid substitution of SEQ ID NO: 6 at residues 399 and 449. In one embodiment, the polypeptide includes the amino acid substitutions 399Q and 449Q. In several embodiments, the polypeptide includes Q at position 399 and Q at position 449, based on the numbering of SEQ ID NO: 6.

[0074] In further embodiments of the polypeptide of the first aspect of this disclosure, the polypeptide comprises 358S and 463T. In some embodiments, the polypeptide comprises (i) S at position 358 and (ii) T at position 463, or any combination of (i) to (ii), based on the numbering of Sequence ID No. 6.

[0075] In one embodiment of the polypeptide of the first aspect of this disclosure, the polypeptide comprises 262E, 269T, 354Q, 358S, 399Q, 449Q, and 463T. In some embodiments, the polypeptide comprises (i) E at position 262, (ii) T at position 269, (iii) Q at position 354, (iv) S at position 358, (v) Q at position 399, (vi) Q at position 449, and (vii) T at position 463, or any combination of (i) to (vii), based on the numbering in Sequence ID No. 6. These polypeptides are comprehensively characterized in the examples disclosed in WO2016 / 200880, as exemplified by the polypeptides shown as Kuma030 and its variants. In another embodiment of the polypeptide of the first aspect of this disclosure, the polypeptide comprises 319A, 368F, 399Q, 449Q, and 463T. In some embodiments, the polypeptide comprises (i) A at position 319, (ii) F at position 368, (iii) Q at position 399, (iv) Q at position 449, and (v) T at position 463, or any combination of (i) to (v), based on the numbering in Sequence ID No. 6. These polypeptides are comprehensively characterized in the examples disclosed in WO2016 / 200880, as exemplified by the polypeptides shown as Kuma040 and its variants. In further embodiments of the polypeptides of the first embodiment of this disclosure, the polypeptide comprises 262E, 269T, 270V, 354Q, 358S, 399Q, and A449Q. In some embodiments, the polypeptide comprises, based on the numbering of Sequence ID No. 6, (i) E at position 262, (ii) T at position 269, (iii) V at position 270, (vi) Q at position 354, (v) S at position 358, (vi) Q at position 399, and (vii) Q at position 449, or any combination of (i) to (vii). These polypeptides are comprehensively characterized in the examples disclosed in WO2016 / 200880, as exemplified by the polypeptides shown as Kuma050 and its variants.In one embodiment of the polypeptide of the first aspect of this disclosure, the polypeptide comprises 262E, 269T, 320M, 354Q, 358S, 399Q, 449Q, and 463T. In some embodiments, the polypeptide comprises (i) E at position 262, (ii) T at position 269, (iii) M at position 320, (vi) Q at position 354, (v) S at position 358, (vi) Q at position 399, and (vii) Q at position 449, or any combination of (i) to (vii), based on the numbering in Sequence ID No. 6. These polypeptides are comprehensively characterized in the examples disclosed in WO2016 / 200880, as exemplified by the polypeptides shown as Kuma060 and its variants. In further embodiments of the polypeptides of the first aspect of this disclosure, the polypeptide comprises 319A, 320M, 368F, 399Q, 449Q, and 463T. In some aspects, the polypeptide comprises (i) A at position 319, (ii) M at position 320, (iii) F at position 368, (v) Q at position 399, and (v) Q at position 449, or any combination of (i) to (v), based on the numbering in Sequence ID No. 6. These polypeptides are comprehensively characterized in the examples disclosed in WO2016 / 200880, as exemplified by the polypeptides shown as Kuma070 and its variants. As used herein, the terms “Kuma020,” “Kuma030,” “Kuma040,” “Kuma050,” and “Kuma070” mean the same polypeptide having the same notation as disclosed in WO2016 / 200880.

[0076] In another embodiment of the polypeptide of the first embodiment of this disclosure, the polypeptide includes the amino acid substitution of SEQ ID NO: 6 at the position of one or more amino acids selected from the group consisting of 105, 171, 172, 173, 174, and 456. In one embodiment, the amino acid substitution is 105H; 171R, A, or S; 172R, A, or S; 173R or S, 174S, and / or 456V. In some embodiments, the polypeptide includes, based on the numbering of SEQ ID NO: 6, (i) H at position 105, (ii) R, A, or S at position 171, (iii) R, A, or S at position 172, (iv) R or S at position 173, (v) S at position 174, (vi) V at position 456, or any combination of (i) to (vi). In another embodiment, the amino acid substitution is 171R, 172R, and / or 456V. In some embodiments, the polypeptide includes, based on the numbering of Sequence ID No. 6, (i) R at position 171, (ii) R at position 172, (iii) V at position 456, or (iv) any combination of (i) to (iii).

[0077] In one embodiment of the polypeptide according to the second aspect of this disclosure, the polypeptide includes one or more amino acid substitutions of SEQ ID NO: 3 in one or more residues selected from the group consisting of 32D / N / Q / H, 73E, 79S / T / A, 80L / T, 81A / T / V, 130A, 165E / Q / R / Y, 169S / Q / T, 179F / Q, 210Q, 213S / Q, 217S, 235K, 260E / N / Q, 272R, and 274A / L / M / Q / R / T / V. In another embodiment of the polypeptide according to the second aspect of this disclosure, the polypeptide includes the amino acid substitutions of SEQ ID NO: 3 in residues 210 and 260. In a further embodiment of the polypeptide according to the second aspect of this disclosure, the polypeptide includes the amino acid substitutions 210Q and 260Q. In some embodiments, the polypeptide includes (i) Q at position 210, (ii) Q at position 260, or any combination of (i) to (ii), based on the numbering in Sequence ID No. 3. In one embodiment of the polypeptide of the second embodiment of this disclosure, the polypeptide includes 169S and 274T (Kuma020 genus). In such embodiments, the polypeptide includes (i) S at position 169, (ii) T at position 274, or (iv) any combination of (i) to (ii), based on the numbering in Sequence ID No. 3. In another embodiment of the polypeptide of the second embodiment of this disclosure, the polypeptide includes 73E, 80T, 165Q, 169S, 210Q, 260Q, and 274T (Kuma030 genus). In this embodiment, the polypeptide includes, based on the numbering of Sequence ID No. 3, (i) E at position 73, (ii) T at position 80, (iii) Q at position 165, (iv) S at position 169, (v) Q at position 210, (vi) Q at position 260, and (vii) T at position 274, or any combination of (i) to (vii). In a further embodiment of the polypeptide of the second embodiment of this disclosure, the polypeptide includes 130A, 179F, 210Q, 260Q, and 274T (Genus Kuma040). In this embodiment, the polypeptide includes, based on the numbering of Sequence ID No. 3, (i) A at position 130, (ii) F at position 179, (iii) Q at position 210, (iv) Q at position 260, (v) T at position 274, or any combination of (i) to (v).In a further embodiment of the polypeptide of the second aspect of this disclosure, the polypeptide comprises 73E, 80T, 81V, 165Q, 169S, 210Q, and 260Q (Genus Kuma050). In such embodiments, the polypeptide comprises, based on the numbering of Sequence ID No. 3, (i) E at position 73, (ii) T at position 80, (iii) V at position 81, (iv) Q at position 165, (v) S at position 169, (vi) Q at position 210, (vii) Q at position 260, or any combination of (i) to (vii). In one embodiment of the polypeptide of the second aspect of this disclosure, the polypeptide comprises 73E, 80T, 320M, 165Q, 169S, 210Q, 260Q, and 274T (Genus Kuma060). In such embodiments, the polypeptide includes, based on the numbering of Sequence ID No. 3, (i) E at position 73, (ii) T at position 80, (iii) M at position 320, (iv) Q at position 165, (v) S at position 169, (vi) Q at position 210, (vii) Q at position 260, and (viii) T at position 274, or any combination of (i) to (vii). In another embodiment of the polypeptide of the second embodiment of this disclosure, the polypeptide includes 130A, 131M, 179F, 210Q, 260Q, and 274T (genus Kuma070). In such embodiments, the polypeptide includes, based on the numbering of SEQ ID NO: 3, (i) A at position 130, (ii) M at position 131, (iii) F at position 179, (iv) Q at position 210, (v) Q at position 260, (vi) T at position 274, or any combination of (i) to (vi). In yet another embodiment of the polypeptide of the second embodiment of this disclosure, the polypeptide includes the amino acid substitution of SEQ ID NO: 3 at the position of one or more amino acids selected from the group consisting of 267. In one embodiment, the amino acid substitution is 267V. In such embodiments, the polypeptide includes V at position 267, based on the numbering of SEQ ID NO: 3.

[0078] In further embodiments of the polypeptides of any aspect of this disclosure, the polypeptide further comprises a histidine tag at the C-terminus of the polypeptide to facilitate the isolation of the polypeptide. Any suitable histidine tag can be used. In one embodiment, the tag binds to a TEV protease cleavage site (ENLYFQS) (SEQ ID NO: 18), enabling efficient removal by TEV protease after purification. For example, the tag may contain or be derived from the amino acid sequence GSTENLYFQSGALEHHHHHH (SEQ ID NO: 17). In another embodiment, the histidine tag is a cleavable histidine tag, enabling even easier removal of the His tag. In one embodiment, the cleavable histidine tag is an amino acid sequence X N PQ(L / Q)PX N HHHHHH[where, X N It is a linker consisting of 1 to 25 amino acid residues. It includes ] (SEQ ID NO: 15). In one non-limiting example, a cleavable histidine tag includes the amino acid sequence GSSGSSGSQPQLPYGSSGSSGSHHHHHH (SEQ ID NO: 16).

[0079] In any embodiment of the polypeptides of this disclosure, the amino acid substitutions may include one or more substitutions listed in Table 2 or 3, compared to SEQ ID NO: 6 or SEQ ID NO: 3. Substitutions at these positions have generally been found to be well-tolerated (i.e., generally have little to no effect on activity) and, in some cases, to increase the activity of the polypeptides of this disclosure by more than 20%. [Table 2]

[0080] In another embodiment of any aspect of the polypeptide of the present disclosure, the amino acid substitution may include one or more substitutions listed in Table 3, compared to SEQ ID NO: 6 or SEQ ID NO: 3. [Table 3]

[0081] In another embodiment of any aspect of the polypeptide of the Disclosure, the amino acids at each residue of the polypeptide of the Disclosure may be as shown in Table 4, which lists all possible mutations at each position in the polypeptide enzyme as predicted by computer mutagenesis analysis. As described in the examples disclosed in WO2016 / 200880, the mutations were tested at each position found in the active site (residues 261-264, 266-267, 270, 317-320, 350-354, 368, 397, 403-404, 446, 448, 456, and 463-468) using denaturing primers that test the effect of various amino acid substitutions on activity. Mutations that did not interfere with activity can be incorporated into the polypeptide of the Disclosure, as reflected in Table 4. [Table 4-1] [Table 4-2] [Table 4-3] [Table 4-4] [Table 4-5] [Table 4-6] [Table 4-7] [Table 4-8] [Table 4-9] [Table 4-10]

Table 4-11

Table 4-12

Table 4-13

Table 4-14

Table 4-15

[0082] [[ID=Z8]]In some embodiments, the polypeptide sequences disclosed herein further comprise a histidine tag. In some embodiments, the histidine tag is fused to the polypeptide at the C-terminus of the polypeptide. Any suitable histidine tag can be used. In some embodiments, the histidine tag is linked to a TEV protease cleavage site (ENLYFQS) (SEQ ID NO: 18) to enable efficient removal of the histidine tag by TEV protease after purification., For example, the tag can comprise, or consist of, the amino acid sequence GSTENLYFQSGALEHHHHHH (SEQ ID NO: 17). In another embodiment, a cleavable histidine tag is incorporated at the C-terminus of the polypeptide sequence comprising N PQ(L / Q)PX N HHHHHH [where X N is a linker of 1 to 25 amino acid residues.](SEQ ID NO: 15). In one non-limiting example, the cleavable histidine tag comprises the amino acid sequence GSSGSSGSQPQLPYGSSGSSGSHHHHHH (SEQ ID NO: 16).

[0083] As shown in Table 5, point substitutions corresponding to the Kuma010 / 011 amino acid sequence can affect catalytic activity. Table 5 lists the effectiveness of individual mutations in catalyzing the degradation of various gliadin peptide sequences. Examples disclosed in WO2016 / 200880 provide further data on specific individual and combinational mutants. [Table 5-1] [Table 5-2]

[0084] In certain embodiments, the disclosure provides polypeptides comprising at least one mutation that improves polypeptide production. In some embodiments, the mutation that improves production results in one of three categories of improvement: 1. modification of the purification method; 2. increased yield; and 3. simplification of analysis by reducing the likelihood of enzymatic self-processing occurring during purification. Adding a His tag that can be removed by proteolytic activity to the polypeptides disclosed herein results in Category 1, the R105H mutant appears to improve yield by approximately twofold, and this mutation is classified as Category 2, while mutations at positions 171–174 classify these mutants as Category 3.

[0085] As used throughout this application, the term “polypeptide” is used in its broadest sense to mean a sequence of subunit amino acids, whether naturally occurring or synthetically derived. Polypeptides of this disclosure may comprise L-amino acids, D-amino acids (resistant to L-amino acid-specific proteases in vivo), or combinations of D and L-amino acids. Polypeptides described herein may be chemically synthesized or expressed by recombination. Polypeptides may be conjugated to other compounds, for example, by PEGylation, HESation, PASation, or glycosylation, to promote an increase in half-life in vivo. Such conjugations may be covalent or non-covalent, as understood by those skilled in the art. In some embodiments, polypeptides are conjugated to any other suitable linker, including but not limited to any linker (such as a FLAG or His tag) available for purification or detection.

[0086] A. Nucleic acid In another aspect, the Disclosure provides isolated nucleic acids encoding polypeptides of any aspect of the Disclosure. An exemplary nucleic acid encoding Kuma062-M is shown below. Sequence ID 22

[0087] Isolated nucleic acid sequences may include RNA or DNA. As used herein, “isolated nucleic acid” means a sequence that has been removed from its surrounding normal nucleic acid sequence, either within a genome or within a cDNA sequence. Such isolated nucleic acid sequences may include, but are not limited to, poly(A) sequences, modified Kozak sequences, and further sequences useful for promoting the expression and / or purification of encoded proteins, including, but not limited to, sequences encoding epitope tags, export signals, and secretion signals, nuclear localization signals, and plasma membrane localization signals. Based on the teachings herein, it will be obvious to those skilled in the art which nucleic acid sequences encode the polypeptides of this disclosure.

[0088] In a further embodiment, the Disclosure provides a nucleic acid expression vector comprising an isolated nucleic acid of any embodiment of the Disclosure operably ligated to a preferred regulatory sequence. A “recombinant expression vector” includes a vector operably ligating a nucleic acid coding region or a gene to any regulatory sequence capable of influencing the expression of a gene product. The “regulatory sequence” operably ligated to a nucleic acid sequence in the Disclosure is a nucleic acid sequence capable of influencing the expression of a nucleic acid molecule. The regulatory sequence does not need to be adjacent to the nucleic acid sequence, provided it has the function of directing the expression of the nucleic acid sequence. Therefore, for example, an intervening, untranslated but transcribed sequence may exist between the promoter sequence and the nucleic acid sequence, and the promoter sequence may still be considered “operably ligated” to the coding sequence. Other such regulatory sequences include, but are not limited to, polyadenylation signals, termination signals, and ribosome binding sites. Such expression vectors can be any type known in the art, including, but are not limited to, plasmid and virus-based expression vectors. In mammalian systems, the regulatory sequences used to drive the expression of the disclosed nucleic acid sequences may be constitutive (driven by any of a variety of promoters, including but not limited to CMV, SV40, RSV, actin, and EF) or inducible (driven by any of a number of inducible promoters, including but not limited to tetracycline, ecdysone, and steroid-responsive). The construction of expression vectors for use in transfection of prokaryotic cells is also well known in the art and can therefore be achieved by standard techniques.See, for example, Sambrook, Fritsch, and Maniatis, in: Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press, 1989; Gene Transfer and Expression Protocols, pp. 109-128, ed. EJ Murray, The Humana Press Inc., Clifton, NJ; and the Ambion 1998 Catalog (Ambion, Austin, TX). The expression vector must be replicable within the host organism, either as an episome or by integration into host chromosomal DNA. In a preferred embodiment, the expression vector comprises a plasmid. However, this disclosure is intended to include other expression vectors that perform equivalent functions, such as viral vectors.

[0089] B. Host cells In another embodiment, the Disclosure provides recombinant host cells comprising the nucleic acid expression vector of the Disclosure. Any host cell capable of producing recombinant proteins can be used in the manner disclosed herein. The host cell may be either prokaryotic or eukaryotic. In some embodiments, the host cell is a prokaryotic cell. Non-limiting examples of suitable prokaryotic host cells include Escherichia coli, Bacillus subtilis, Caulobacter crescentus, Rodhobacter sphaeroides, Pseudoalteromonas haloplanktis, Shewanella sp. strain Ac10, Pseudomonas fluorescensi Pseudomonas putida, Pseudomonas aeruginosa, Halomonas elongata, Chromohalobacter salexigens, Streptomyces lividans, Streptomyces griseus, Nocardia lactamdurans, Mycobacterium smegmatis, Corynebacterium glutamicum, Corynebacterium ammoniagenes, Brevibacterium lactofermentum, Bacillus subtilis, Bacillus brevis, Bacillus megaterium, Bacillus licheniformis, Bacillus Examples include amyloliquefaciens, Lactococcus lactis, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus reuteri, and Lactobacillus gasseri. In some embodiments, the host cell is a eukaryotic cell. Non-limiting examples of suitable eukaryotic host cells include Saccharomyces cerevisiae and Aspergillus nidulans. The cells can be transfected or transduced transiently or stably.Such transfection and transduction of expression vectors into prokaryotic and eukaryotic cells can be achieved by any technique known in the art, including but not limited to standard bacterial transformation, calcium phosphate coprecipitation, electroporation, or liposome-mediated, DEAE-dextran-mediated, polycation-mediated, or virus-mediated transfection. For example, Molecular Cloning: A Laboratory Manual (Sambrook, et al., 1989, Cold Spring Harbor Laboratory Press), Culture of Animal Cells: A Manual of Basic Technique, 2. nd See Ed. (RIFreshney. 1987. Liss, Inc. New York, NY). Methods for producing polypeptides according to this disclosure are further part of this disclosure. The method comprises (a) culturing a host according to this embodiment of this disclosure under conditions for polypeptide expression, and (b) optionally recovering the expressed polypeptide. The expressed polypeptide can be recovered from a cell-free extract, a cell pellet, or a culture medium. Methods for purifying recombinantly expressed polypeptides are well known to those skilled in the art.

[0090] C. Pharmaceutical Compositions In further embodiments, the Disclosure provides a pharmaceutical composition comprising a polypeptide, nucleic acid, nucleic acid expression vector, and / or recombinant host cell in any embodiment or embodiment of the Disclosure, and a pharmaceutically acceptable carrier. The pharmaceutical composition of the Disclosure can be used, for example, in the methods of the Disclosure described below. In addition to the polypeptide, nucleic acid, etc. of the Disclosure, the pharmaceutical composition may also comprise (a) an antifreeze, (b) a surfactant, (c) a filler, (d) a tonicity modifier, (e) a stabilizer, (f) a preservative, and / or (g) a buffer.

[0091] In some embodiments, the buffer in the pharmaceutical composition is Tris buffer, histidine buffer, phosphate buffer, citrate buffer, or acetate buffer. The pharmaceutical composition may also contain an antifreeze, such as sucrose, sorbitol, or trehalose. In certain embodiments, the pharmaceutical composition contains preservatives, such as benzalkonium chloride, benzethonium, chlorhexidine, phenol, m-cresol, benzyl alcohol, methylparaben, propylparaben, chlorobutanol, o-cresol, p-cresol, chlorocresol, phenylmercury nitrate, thimerosal, benzoic acid, and various mixtures thereof. In other embodiments, the pharmaceutical composition contains a filler such as glycine. In yet another embodiment, the pharmaceutical composition includes surfactants, such as polysorbate-20, polysorbate-40, polysorbate-60, polysorbate-65, polysorbate-80, polysorbate-85, poloxamer 188, sorbitan monolaurylate, sorbitan monopalmitate, sorbitan monostearate, sorbitan monooleate, sorbitan trilaurate, sorbitan tristearate, sorbitan trioleaste, or combinations thereof. The pharmaceutical composition may also include tonic modifiers, such as compounds that make the formulation substantially isotonic or isosmotic in human blood. Exemplary tonic modifiers include sucrose, sorbitol, glycine, methionine, mannitol, dextrose, inositol, sodium chloride, arginine, and arginine hydrochloride. In other embodiments, the pharmaceutical composition further includes stabilizers, for example, molecules that, when combined with the protein of interest, substantially prevent or reduce the chemical and / or physical instability of the protein of interest in lyophilized or liquid form. Exemplary stabilizers include sucrose, sorbitol, glycine, inositol, sodium chloride, methionine, arginine, and arginine hydrochloride.

[0092] The polypeptides, nucleic acids, etc. of this disclosure may be merely activators in the pharmaceutical composition, or the composition may further contain one or more other activators appropriate for the intended use.

[0093] The pharmaceutical compositions described herein generally comprise a combination of the compounds described herein with a pharmaceutically acceptable carrier, diluent, or excipient. Such compositions are substantially free of pharmaceutically unacceptable components, i.e., they contain amounts of pharmaceutically unacceptable components less than those permitted by U.S. regulatory requirements at the time of filing this application. In some embodiments of this invention, where the compounds are soluble in water or suspended, the compositions optionally further comprise additional pharmaceutically acceptable carriers, diluents, or excipients. In other embodiments, the pharmaceutical compositions described herein are solid pharmaceutical compositions (e.g., tablets, capsules, etc.).

[0094] The compositions described herein may also be provided as dietary supplements, as described by the U.S. regulatory authorities.

[0095] These compositions can be prepared by methods well known in the pharmaceutical technology field and administered by any preferred route. In preferred embodiments, the pharmaceutical compositions and formulations are designed for oral administration. Conventional pharmaceutical carriers, aqueous, powder, or oily bases, thickeners, etc., may be essential or desirable.

[0096] Pharmaceutical compositions may exist in any preferred form, including but not limited to tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as solids or in liquid media), ointments containing up to 10% by weight of the active compound, soft and hard gelatin capsules, sterile injection solutions, and sterile packaging powders.

[0097] 3. Method of Disclosure In another aspect, the Disclosure provides a method for treating celiac sprue or non-celiac gluten sensitivity (NCGS), comprising administering to an individual suffering from celiac sprue or NCGS one or more polypeptides selected from the group consisting of polypeptides of the Disclosure in an amount effective to treat the celiac sprue or NCGS, or processing food for consumption by an individual suffering from celiac sprue or NCGS using one or more of these polypeptides.

[0098] In certain embodiments, the method includes administering to a subject suffering from celiac sprue or NCGS a polypeptide containing an amino acid sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% sequence identity with respect to the amino acid sequence shown in SEQ ID NO: 1. In certain embodiments, the method includes administering to a subject suffering from celiac sprue or NCGS a polypeptide containing an amino acid sequence having at least 90% sequence identity with respect to the amino acid sequence shown in SEQ ID NO: 1. In certain embodiments, the method includes administering to a subject suffering from celiac sprue or NCGS a polypeptide containing an amino acid sequence having at least 95% sequence identity with respect to the amino acid sequence shown in SEQ ID NO: 1. In certain embodiments, the method includes administering to a subject suffering from celiac sprue or NCGS a polypeptide containing an amino acid sequence having at least 96% sequence identity with respect to the amino acid sequence shown in SEQ ID NO: 1. In certain embodiments, the method includes administering to a subject suffering from celiac sprue or NCGS a polypeptide containing an amino acid sequence having at least 97% sequence identity with respect to the amino acid sequence shown in SEQ ID NO: 1. In certain embodiments, the method includes administering to a subject suffering from celiac sprue or NCGS a polypeptide containing an amino acid sequence having at least 98% sequence identity with respect to the amino acid sequence shown in SEQ ID NO: 1. In certain embodiments, the method includes administering to a subject suffering from celiac sprue or NCGS a polypeptide containing an amino acid sequence having at least 99% sequence identity with respect to the amino acid sequence shown in SEQ ID NO: 1. In certain embodiments, the method includes administering to a subject suffering from celiac sprue or NCGS a polypeptide containing an amino acid sequence shown in SEQ ID NO: 1.

[0099] In certain embodiments, the method includes administering to a subject suffering from celiac sprue or NCGS a polypeptide containing an amino acid sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% sequence identity with respect to the amino acid sequence shown in SEQ ID NO: 8. In certain embodiments, the method includes administering to a subject suffering from celiac sprue or NCGS a polypeptide containing an amino acid sequence having at least 90% sequence identity with respect to the amino acid sequence shown in SEQ ID NO: 8. In certain embodiments, the method includes administering to a subject suffering from celiac sprue or NCGS a polypeptide containing an amino acid sequence having at least 95% sequence identity with respect to the amino acid sequence shown in SEQ ID NO: 8. In certain embodiments, the method includes administering to a subject suffering from celiac sprue or NCGS a polypeptide containing an amino acid sequence having at least 96% sequence identity with respect to the amino acid sequence shown in SEQ ID NO: 8. In certain embodiments, the method includes administering to a subject suffering from celiac sprue or NCGS a polypeptide containing an amino acid sequence having at least 97% sequence identity with respect to the amino acid sequence shown in SEQ ID NO: 8. In certain embodiments, the method includes administering to a subject suffering from celiac sprue or NCGS a polypeptide containing an amino acid sequence having at least 98% sequence identity with respect to the amino acid sequence shown in SEQ ID NO: 8. In certain embodiments, the method includes administering to a subject suffering from celiac sprue or NCGS a polypeptide containing an amino acid sequence having at least 99% sequence identity with respect to the amino acid sequence shown in SEQ ID NO: 8. In certain embodiments, the method includes administering to a subject suffering from celiac sprue or NCGS a polypeptide containing an amino acid sequence showing respect to

[0100] In a particular embodiment, the method involves administering to a subject suffering from celiac sprout or NCGS a polypeptide comprising an amino acid sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% sequence identity to the amino acid sequence shown in SEQ ID NO: 1, wherein the polypeptide comprises the amino acid sequence shown in SEQ ID NO: 8, and the polypeptide comprises Ser at the amino acid residue corresponding to amino acid 278 of SEQ ID NO: 3, Glu at the amino acid residue corresponding to amino acid 78 of SEQ ID NO: 3, and Asp at the amino acid residue corresponding to amino acid 82 of SEQ ID NO: 3.

[0101] In a particular embodiment, the Disclosure provides a method for breaking down gluten in a food, comprising breaking down the gluten in the food by contacting the food with a polypeptide described herein in an amount effective for breaking down the gluten.

[0102] In a particular embodiment, the present disclosure provides a method for breaking down gluten in a food, comprising breaking down the gluten in the food by contacting the food with a pharmaceutical composition described herein in an amount effective for breaking down the gluten.

[0103] In certain embodiments, the Disclosure provides a method for grading gliadin in a food, comprising grading gluten in the food by contacting the food with a polypeptide or pharmaceutical composition described herein in an amount effective for grading gliadin. In some embodiments, the method grades at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 99%, or about 100% of the gluten or gliadin in the food. In some embodiments, the method disclosed herein can grade gluten or gliadin in a food in less than about 1.5 hours, less than about 1 hour, less than about 45 minutes, less than about 40 minutes, less than about 30 minutes, less than about 25 minutes, less than about 20 minutes, less than about 15 minutes, less than about 10 minutes, or less than about 5 minutes. In some embodiments, the methods disclosed herein can decompose gluten or gliadin in food at pH values ​​of less than about 6.5, less than about 6.0, less than about 5.5, less than about 5.0, less than about 4.5, less than about 4.0, less than about 3.5, or less than about 3.0.

[0104] The inventors of this disclosure have found that the polypeptides of this disclosure are capable of grading the proline (P) and glutamine (Q)-rich components of gluten known as "gliadin," which are thought to be responsible for the majority of the immune response in most celiac sprue patients. Compared to Kuma010 / 011 and other polypeptides disclosed as useful for the treatment of celiac sprue (WO2015 / 023728), the polypeptides of this disclosure exhibit superior activity at pH 4 in grading peptides having the PQLP (SEQ ID NO: 9) or PQQP (SEQ ID NO: 10) motif (such as PFPQPQLPY (SEQ ID NO: 11) and / or PFPQPQQPF (SEQ ID NO: 12), which are representative substrates of gliadin). Therefore, the polypeptides of this disclosure constitute a significantly improved therapeutic agent for the treatment of celiac sprue and NCGS.

[0105] In certain embodiments, the pharmaceutically active compositions and / or formulations of the polypeptides disclosed herein are administered orally. Non-limiting examples of routes of oral administration include the use of tablets, pills, lozenges, elixirs, suspensions, emulsions, solutions, syrups, or any combination thereof. In certain embodiments, the pharmaceutically active compositions comprising the polypeptides disclosed herein are administered to a subject before the subject digests a substance, such as food containing one or more gluten proteins. In some embodiments, the pharmaceutically active compositions comprising the polypeptides disclosed herein are administered to a subject simultaneously with the subject digesting a substance, such as food containing one or more gluten proteins. In some embodiments, the pharmaceutically active compositions comprising the polypeptides disclosed herein are administered to a subject after the subject has digested a substance, such as food containing one or more gluten proteins.

[0106] The medication regimen may be adjusted to produce the optimal desired response (e.g., therapeutic or prophylactic response). A preferred dose range may be, for example, 0.1 ug / kg to 100 mg / kg body weight, or 0.5 ug / kg to 50 mg / kg, 1 ug / kg to 25 mg / kg, or 5 ug / kg to 10 mg / kg body weight. The polypeptide may be delivered in a single bolus or in two or more doses (e.g., two, three, four, five, or more doses), as determined by the attending physician.

[0107] This disclosure is further illustrated by the following embodiments, but this should not be construed as limiting. All cited sources, such as references, publications, databases, and database entries cited herein, are incorporated by reference to this application, even if not explicitly stated in the citation. In the event of any conflict between the description of a cited source and this application, the description of this application shall prevail.

[0108] Chapter and table headings are not intended to be restrictive. [Examples]

[0109] Example 1: Gluten degradation in whole wheat bread by Kuma062-M This study demonstrates that Kuma062-M can effectively break down gluten.

[0110] The laboratory simulation of gastric digestion was designed to represent digestion in the human stomach. Bread samples were first ground in artificial saliva to simulate chewing, and then acidified with hydrochloric acid. Unless otherwise specified, the pH of gastric digestion was 3.6–4.5. Samples were blended to ensure the ability to properly present the material through the tip of a narrow pipette (because ELISA uses very small volumes as needed), but where indicated, samples were simply ground. Dietary samples had a final total volume of 400–800 mL before initiating the digestion process, with aliquots of the meal fractionated into individual tubes. Digestion was initiated by adding pepsin and / or gliadinase Kuma062-M. The samples were then incubated at body temperature (37°C) at the indicated time points. In most whole-wheat bread / meal digestion experiments, the average lag time for food churning in the stomach before release into the duodenum via the pyloric valve is 30-60 minutes; therefore, samples were allowed to digest for 30 minutes. Enzyme activity was terminated at the end of the digestion period by heating to a temperature that irreversibly inactivates all present enzymes.

[0111] Gluten in digested samples was quantified using either the R5 Ridascreen® ELISA kit (R-Biopharm) or the G12 Glutentox® ELISA kit (Biomedal), following the manufacturer's instructions. These kits are based on either the R5 monoclonal antibody (recognizing QQPFP) or the G12 monoclonal antibody (recognizing QPQLPY) (SEQ ID NOs. 19 and 20, respectively). These epitopes are present in the majority of the immunogenic fragments of gluten, including all immunodominant fragments. The G12 antibody detects the immunogenic region of α-gliadin, while the R5 antibody detects the immunogenic regions of ω-gliadin and γ-gliadin. Although the R5 ELISA method has been shown to be effective in estimating gluten concentrations in unprocessed foods, we found that the fraction of gluten recognized by the R5 antibody decreases, at least partially, after incubation of gluten with pepsin. Pepsin has been shown to be less effective against the 33-mer fragment LQLQPFPQPQLPYPQPQLPYPQPQLPYPQPQPF8 (SEQ ID NO: 13), a fraction recognized by the G12 antibody. Unlike the R5 antibody, the detection of gluten epitopes by the G12 antibody was frequently observed to be unaffected or even slightly increased by pepsin digestion. This suggests that pepsin treatment makes the QPQLPY (SEQ ID NO: 20) epitope-containing region of gluten more available to the G12 antibody. In this example, both ELISA-based methods were used to evaluate the ability of gliadinase to reduce the levels of all three families of immunogenic gliadins: α, ω, and γ gliadins. In one of the experiments detailed below, an in-house G12-based ELISA method was used. Although this in-house developed method is less expensive than commercially available kits, it is less reliable for the quantification of low concentrations of gluten. Therefore, this method was used solely to evaluate the relative differences between samples.

[0112] Table 6 shows that Kuma062-M can effectively break down gluten in simulated gastric digestion. Pepsin can break down gluten in simulated gastric digestion even in small amounts. [Table 6]

[0113] Example 2: Gluten breakdown in whole wheat bread by Kuma062-M at different pH levels. This study aims to evaluate the gluten-breaking ability of Kuma062-M at different pH values.

[0114] The protocol for simulated gastric digestion was largely the same as that in Example 1. Bread slurries were prepared at the following pH levels: 3.9, 4.5, 5.0, 5.5, and 5.9. pH 5.9 was the pH of the bread after grinding with artificial saliva and then adding only water to the slurry without HCl.

[0115] Table 7 shows that Kuma062-M can efficiently break down gluten at various pH values. [Table 7]

[0116] Example 3: Gluten breakdown in fast food meals by Kuma062-M This study aims to evaluate whether Kuma062M can maintain significant activity against gluten even in the presence of other food proteins.

[0117] The protocol for simulated gastric digestion was largely the same as that in Example 1. The vanilla milkshake was estimated to contain 10 grams of protein (approximately, compared to a similar-sized milkshake from McDonald's®), while the hamburger patty was estimated to contain 7 grams of protein. The pH of the meals during gastric digestion was 4.0–4.5. The amount of bun in the hamburger in the control meal was adjusted to the same amount as the bun in the hamburger and milkshake meals. The volume of the hamburger and milkshake meals during gastric digestion was 500 mL. The control meal was also adjusted to 500 mL. Aliquots of the ground and blended meal slurry were fractionated into smaller tubes, and glutenase enzyme and pepsin were added to these aliquots. For Kuma062-M, the enzyme concentrations were 700 μg / mL or 70 μg / mL. The meals were digested for 30 minutes or 5 minutes. Aspergillus niger-derived prolyl endopreteases (AN-PEP) and EPB2 / SCPEP were also included in this study.

[0118] Tables 8 and 9 show that Kuma062-M can effectively degrade gluten in the presence of other food proteins. Table 8 shows the results using the G12 ELISA assay. Table 9 shows the results using the R5 ELISA assay. [Table 8] [Table 9]

[0119] Equal parts Those skilled in the art will be able to recognize or confirm many equivalents to particular aspects of this disclosure by using only routine experiments. Such equivalents are intended to be covered by the following claims.

[0120] manner E1. A polypeptide comprising an amino acid sequence having at least approximately 75%, at least approximately 80%, at least approximately 85%, at least approximately 90%, at least approximately 95%, at least approximately 96%, at least approximately 97%, at least approximately 98%, at least approximately 99%, or at least approximately 100% sequence identity with respect to the amino acid sequence shown in Sequence ID No. 1.

[0121] E2. The polypeptide according to E1, comprising an amino acid sequence having at least 85% sequence identity with respect to the amino acid sequence shown in Sequence ID No. 1.

[0122] E3. A polypeptide according to E1 or E2, comprising an amino acid sequence having at least 90% sequence identity with respect to the amino acid sequence shown in Sequence ID No. 1.

[0123] E4. A polypeptide according to any one of E1 to E3, comprising an amino acid sequence having at least 95% sequence identity with respect to the amino acid sequence shown in Sequence ID No. 1.

[0124] E5. A polypeptide according to any one of E1 to E4, comprising an amino acid sequence having at least 99% sequence identity with respect to the amino acid sequence shown in Sequence ID No. 1.

[0125] E6. A polypeptide containing the amino acid sequence shown in Sequence ID No. 1, as described in any one of E1-5.

[0126] E7. A polypeptide described in any one of E1 to E6, wherein the amino acid residue corresponding to amino acid 467 of SEQ ID NO: 6 is Ser.

[0127] E8. A polypeptide described in any one of E1 to E7, wherein the amino acid residue corresponding to amino acid 267 of sequence number 6 is Glu.

[0128] E9. A polypeptide described in any one of E1 to E8, wherein the amino acid residue corresponding to amino acid 271 of sequence number 6 is Asp.

[0129] E10. A polypeptide capable of cleaving gliadin, as described in any one of E1 to E9.

[0130] E11. A polypeptide comprising an amino acid sequence having at least approximately 75%, at least approximately 80%, at least approximately 85%, at least approximately 90%, at least approximately 95%, at least approximately 96%, at least approximately 97%, at least approximately 98%, at least approximately 99%, or at least approximately 100% sequence identity with respect to the amino acid sequence shown in Sequence ID No. 8.

[0131] E12. The polypeptide according to E11, comprising an amino acid sequence having at least 85% sequence identity with respect to the amino acid sequence shown in Sequence ID No. 8.

[0132] E13. A polypeptide according to E11 or E12, comprising an amino acid sequence having at least 90% sequence identity with respect to the amino acid sequence shown in Sequence ID No. 1.

[0133] E14. A polypeptide according to any one of E11 to E13, comprising an amino acid sequence having at least 95% sequence identity with respect to the amino acid sequence shown in Sequence ID No. 8.

[0134] E15. A polypeptide according to any one of E11 to E14, comprising an amino acid sequence having at least 99% sequence identity with respect to the amino acid sequence shown in Sequence ID No. 8.

[0135] E16. A polypeptide described in any one of E11-15, comprising the amino acid sequence shown in Sequence ID No. 8.

[0136] E17. A polypeptide described in any one of E11 to E16, wherein the amino acid residue corresponding to amino acid 278 of SEQ ID NO: 3 is Ser.

[0137] E18. A polypeptide described in any one of E11 to E17, wherein the amino acid residue corresponding to amino acid 78 of sequence number 3 is Glu.

[0138] E19. A polypeptide described in any one of E11 to E18, wherein the amino acid residue corresponding to amino acid 82 of SEQ ID NO: 3 is Asp.

[0139] E20. A polypeptide described in any one of E11-E19 that is capable of cleaving gliadin.

[0140] E21. A polypeptide comprising an amino acid sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% sequence identity with respect to the amino acid sequence shown in Sequence ID No. 1, wherein the polypeptide comprises the amino acid sequence shown in Sequence ID No. 8.

[0141] E22. The polypeptide according to E21, comprising an amino acid sequence having at least 85% sequence identity with respect to the amino acid sequence shown in Sequence ID No. 1.

[0142] E23. A polypeptide according to E21 or E22, comprising an amino acid sequence having at least 90% sequence identity with respect to the amino acid sequence shown in Sequence ID No. 1.

[0143] E24. A polypeptide according to any one of E21 to E23, comprising an amino acid sequence having at least 95% sequence identity with respect to the amino acid sequence shown in Sequence ID No. 1.

[0144] E25. A polypeptide according to any one of E21 to E24, comprising an amino acid sequence having at least 99% sequence identity with respect to the amino acid sequence shown in Sequence ID No. 1.

[0145] E26. A polypeptide described in any one of E21 to E25, comprising the amino acid sequence shown in Sequence ID No. 1.

[0146] E27. A polypeptide described in any one of E21 to E26, wherein the amino acid residue corresponding to amino acid 467 of SEQ ID NO: 6 is Ser.

[0147] E28. A polypeptide described in any one of E21 to E27, wherein the amino acid residue corresponding to amino acid 267 of sequence number 6 is Glu.

[0148] E29. A polypeptide described in any one of E21 to E28, wherein the amino acid residue corresponding to amino acid 271 of SEQ ID NO: 6 is Asp.

[0149] E30. A polypeptide capable of cleaving gliadin, as described in any one of E21-E29.

[0150] E31. A polypeptide according to any one of E1 to E30, further comprising a histidine tag, wherein the histidine tag is fused at the C-terminus of the polypeptide.

[0151] E32. The polypeptide described in E, wherein the histidine tag contains the amino acid sequence (GSTENLYFQSGALEHHHHHH) shown in SEQ ID NO: 17.

[0152] E33. The histidine tag corresponds to the amino acid sequence (X) shown in SEQ ID NO: 15. N PQ(L / Q)PX N HHHHHH) [where X N The polypeptide described in E32 or E33, comprising a cleavable histidine tag, which includes a linker of 1 to 25 amino acid residues, and which also includes a cleavable histidine tag, including ].

[0153] E34. A polypeptide according to any one of E31 to E33, wherein the cleavable histidine tag contains the amino acid sequence shown in SEQ ID NO: 16 (GSSGSSGSQPQLPYGSSGSSGSHHHHHH).

[0154] E35. A nucleic acid molecule encoding one of the polypeptides listed in E1 to E34.

[0155] A nucleic acid expression vector containing the nucleic acid molecules described in E36.E35.

[0156] Recombinant host cells containing the nucleic acid molecule described in E37.E35, or the nucleic acid expression vector described in E36.

[0157] A pharmaceutical composition comprising a polypeptide as described in any one of E1 to E34, a nucleic acid molecule as described in E35, a nucleic acid expression vector as described in E36, a recombinant host cell as described in E37, or any combination thereof, and a pharmaceutically acceptable carrier.

[0158] E39. A method for treating celiac pruce or non-celiac gluten sensitivity (NCGS), comprising administering to an individual suffering from celiac pruce or NCGS an amount effective to treat the celiac pruce or NCGS of a polypeptide according to any one of E1 to E34, a nucleic acid molecule according to claim 35, a nucleic acid expression vector according to claim 36, a recombinant host cell according to claim 37, or a pharmaceutical composition according to claim 38.

[0159] E40. The method according to E39, wherein the polypeptide, the nucleic acid molecule, the nucleic acid expression vector, the recombinant host cell, or the pharmaceutical composition is administered orally.

Claims

1. A polypeptide comprising an amino acid sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% sequence identity to the amino acid sequence set forth in SEQ ID NO:1, wherein the first amino acid at the N-terminus of the polypeptide is Ser (S).

2. A polypeptide comprising an amino acid sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 99%, or about 100% sequence identity to the amino acid sequence set forth in SEQ ID NO:1, wherein the polypeptide does not contain Met (M) at the N-terminus of the polypeptide.

3. A polypeptide comprising an amino acid sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% sequence identity to the amino acid sequence set forth in SEQ ID NO:23, wherein Xaa in SEQ ID NO:23 is not Met (M).

4. 1. A polypeptide comprising an amino acid sequence having at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% sequence identity to the amino acid sequence set forth in SEQ ID NO:1, wherein the first amino acid at the N-terminus of the polypeptide is Ser (S), and the polypeptide comprises the amino acid sequence set forth in SEQ ID NO:

8.

5. 5. The polypeptide of claim 1, wherein the first two N-terminal amino acids of the polypeptide, from N-terminus to C-terminus, are Ser-Asp (SD).

6. The polypeptide according to any one of claims 1 to 5, comprising an amino acid sequence having at least 85% sequence identity to the amino acid sequence shown in SEQ ID NO:

1.

7. The polypeptide according to any one of claims 1 to 6, comprising an amino acid sequence having at least 90% sequence identity to the amino acid sequence shown in SEQ ID NO:

1.

8. The polypeptide according to any one of claims 1 to 7, comprising an amino acid sequence having at least 95% sequence identity to the amino acid sequence shown in SEQ ID NO:

1.

9. The polypeptide according to any one of claims 1 to 8, comprising an amino acid sequence having at least 99% sequence identity to the amino acid sequence shown in SEQ ID NO:

1.

10. A polypeptide according to any one of claims 1 to 97, comprising the amino acid sequence shown in SEQ ID NO:

1.

11. The polypeptide according to any one of claims 1 to 10, wherein the amino acid residue corresponding to amino acid 467 of SEQ ID NO: 1 is Ser.

12. The polypeptide according to any one of claims 1 to 11, wherein the amino acid residue corresponding to amino acid 267 of SEQ ID NO: 1 is Glu.

13. The polypeptide according to any one of claims 1 to 10, wherein the amino acid residue corresponding to amino acid 271 of SEQ ID NO: 1 is Asp.

14. The polypeptide according to any one of claims 1 to 13, wherein the polypeptide is capable of cleaving gliadin.

15. The polypeptide of any one of claims 1 to 14, further comprising a histidine tag, said histidine tag being fused to the C-terminus of said polypeptide.

16. The polypeptide of claim 15, wherein the histidine tag comprises the amino acid sequence shown in SEQ ID NO: 17 (GSTENLYFQSGALEEHHHHHH).

17. The histidine tag has the amino acid sequence shown in SEQ ID NO: 15 (X N PQ(L / Q)PX N HHHHHH) [wherein, X N is a linker of 1 to 25 amino acid residues.

18. 18. The polypeptide of claim 17, wherein the cleavable histidine tag comprises the amino acid sequence set forth in SEQ ID NO: 16 (GSSGSSGSQPQLPYGSSGSSGSHHHHH).

19. A nucleic acid molecule encoding the polypeptide according to any one of claims 1 to 18.

20. 20. A nucleic acid expression vector comprising the nucleic acid molecule of claim 19.

21. 21. A recombinant host cell comprising the nucleic acid molecule of claim 19 or the nucleic acid expression vector of claim 20.

22. The recombinant host cell of claim 21 , wherein the host cell is prokaryotic.

23. The recombinant host cell of claim 21 , wherein the host cell is eukaryotic.

24. A pharmaceutical composition comprising a polypeptide according to any one of claims 1 to 18, a nucleic acid molecule according to claim 19, a nucleic acid expression vector according to claim 20, a recombinant host cell according to any one of claims 21 to 23, or any combination thereof, and a pharma- ceutically acceptable carrier.

25. 21. A pharmaceutical composition for use in a method for treating celiac sprue or non-celiac gluten sensitivity (NCGS) in a subject, comprising an amount of a polypeptide according to any one of claims 1 to 18, a nucleic acid molecule according to claim 19, a nucleic acid expression vector according to claim 20, or a recombinant host cell according to any one of claims 21 to 23 effective to treat said celiac sprue or NCGS, said use comprising administering said pharmaceutical composition to said subject suffering from celiac sprue or NCGS, thereby treating said celiac sprue or NCGS.

26. 21. A pharmaceutical composition for use in a method of reducing inflammation associated with Celiac Sprue or Non-Celiac Gluten Sensitivity (NCGS) in a subject, comprising an amount of a polypeptide according to any one of claims 1 to 18, a nucleic acid molecule according to claim 19, a nucleic acid expression vector according to claim 20, or a recombinant host cell according to any one of claims 21 to 23 effective to reduce inflammation associated with said Celiac Sprue or NCGS, said use comprising administering said pharmaceutical composition to said subject suffering from Celiac Sprue or NCGS thereby reducing said inflammation.

27. 27. The pharmaceutical composition of claim 26, wherein the polypeptide, the nucleic acid molecule, the nucleic acid expression vector, or the recombinant host cell is administered orally.

28. 25. A method for degrading gluten in a food product, comprising degrading the gluten in the food product by contacting the food product with a polypeptide according to any one of claims 1 to 18, or a pharmaceutical composition according to claim 24, in an amount effective to degrade the gluten.

29. A method for degrading gliadin in a food product, comprising degrading the gliadin in the food product by contacting the food product with a polypeptide described in any one of claims 1 to 18, or a pharmaceutical composition described in claim 24, in an amount effective to degrade the gliadin.

30. 30. The method of claim 28 or 29, wherein the method degrades at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 98%, at least about 99%, or about 100% of the gluten or gliadin in the food product.